Skip to main content
Premium Trial:

Request an Annual Quote

Source BioScience's First-Half '08 Revenues Jump 88 Percent

NEW YORK (GenomeWeb News) – Source BioScience today reported that its first-half 2008 revenues increased 88 percent, with a large portion of that growth coming from recent acquisitions.
 
The Nottingham, UK-based genomics and diagnostics services firm brought in revenues of £5.9 million ($10.8 million) for the six-month period ended June 30, compared to revenues of £3.1 million for the first half of 2007. SBS said that of the £2.8 million in revenue growth £2.4 million came from its new Life Science Research division, which includes the acquired businesses of Geneservice and Autogen Bioclear.
 
SBS, formerly called Medical Solutions, purchased Geneservice last year for £3.9 million. It acquired Autogen Bioclear for up to £5.9 million during the first half of 2008.
 
The firm said that sales of gene sequencing, genotyping, and genomic reagents grew 26 percent year over year to £1.6 million, due to the rapid integration of Geneservice “and cross-selling opportunities being identified and exploited.”
 
SBS posted a loss of £181,000, or £.09 per share, compared to a loss of £304,000, or £.15 per share, for the first half of 2007.
 
The company’s administrative expenses increased 40 percent to £2.1 million from £1.5 million, while its R&D expenses increased to £109,000 from £61,000.
 
SBS finished the first half of the year with £8.3 million in cash and cash equivalents.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.